<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03008187</url>
  </required_header>
  <id_info>
    <org_study_id>CLI24-001</org_study_id>
    <nct_id>NCT03008187</nct_id>
  </id_info>
  <brief_title>SEL24/MEN1703 in Patients With Acute Myeloid Leukemia</brief_title>
  <official_title>A Phase I/II Study of SEL24 in Patients With Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Menarini Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medpace, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Theradex</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Menarini Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the clinical trial is to identify the highest dose of SEL24/MEN1703 drug with
      acceptable safety profile and that can be used in patients with Acute Myeloid Leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase I/II, open-label, multi-center, dose escalation study to estimate the maximum tolerated
      dose of SEL24/MEN1703 in patients with Acute Myeloid Leukemia.

      The clinical trial will investigate the safety profile and anti-leukemic activity of
      SEL24/MEN1703 in patients with Acute Myeloid Leukemia and that have no standard therapeutic
      options available.

      The clinical trial encompasses two parts:

        -  Part 1, ascending dose levels: the main purpose of this part of the clinical trial is to
           determine the highest dose of SEL24/MEN1703 considered to be well tolerated.

        -  Part 2, expansion cohort: the main purpose of this part of the clinical trial is to
           assess the safety and anti-leukemia activity of SEL24/MEN1703 given at the highest
           tolerated dose in patient with Acute Myeloid Leukemia.

      Patients participating to the clinical trial will take the study drug as oral capsules once
      daily for 14 consecutive days over a 21-day treatment cycle.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicity (DLT) evaluation</measure>
    <time_frame>DLTs in patients during their first 21-day treatment cycle</time_frame>
    <description>Maximum tolerated dose (MTD) or maximum administered dose (MAD) estimate</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>SEL24/MEN1703</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SEL24/MEN1703 will be given as oral capsules once daily for 14 consecutive days over a 21-day treatment cycle.
Part 1: ascending dose levels (cohort) will be tested in at least 3 patients. Any cohort in which 1 patient experiences a dose-limiting toxicity will be expanded up to 6 patients.
Part 2: testing at the dose of SEL24/MEN1703 which have demonstrated to be adequately tolerated in Part 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SEL24/MEN1703</intervention_name>
    <description>SEL24/MEN1703 will be given as oral capsules once daily for 14 consecutive days over a 21-day treatment cycle.</description>
    <arm_group_label>SEL24/MEN1703</arm_group_label>
    <other_name>SEL24-B489</other_name>
    <other_name>MEN1703</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with diagnosis of Acute Myeloid Leukemia

          -  patients has no standard therapeutic options (newly diagnosed Acute Myeloid Leukemia;
             Relapsed Acute Myeloid Leukemia ans Primary Refractory Acute Myeloid Leukemia).

        Exclusion Criteria:

          -  anti-cancer treatments (including cytotoxic chemotherapy, radiotherapy, hormonal
             therapy, biologic, immunotherapy or investigational drugs) received within 14 days or
             5 half-lives for targeted therapies (whichever is shorter) before first dose of study
             drug (to be supplemented)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Farhad Ravandi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Leukemia, MDACC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Simone Baldini, MD</last_name>
    <phone>+39 345 922 0957</phone>
    <email>SBaldini@menarini-ricerche.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Benjamin Opperman</last_name>
    <phone>+1 (513) 579-9911</phone>
    <phone_ext>12539</phone_ext>
    <email>b.opperman@medpace.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Northside Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott R Solomon, MD</last_name>
      <phone>404-255-1930</phone>
      <email>ssolomon@bmtga.com</email>
    </contact>
    <contact_backup>
      <last_name>Stacey Brown</last_name>
      <phone>404-851-8238</phone>
      <email>stacey.brown@northside.com</email>
    </contact_backup>
    <investigator>
      <last_name>Scott R Solomon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic, Taussig Cancer Institute</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aziz Nazha, MD</last_name>
      <phone>713-792-2121</phone>
      <email>nazhaa@ccf.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen A Strickland Jr, MD, MSCI</last_name>
      <phone>615-936-8422</phone>
      <email>stephen.strickland@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>Stephen A Strickland Jr, MD, MSCI</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael R Savona, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Farhad Ravandi, MD</last_name>
      <phone>713-745-0394</phone>
      <email>fravandi@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Farhad Ravandi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roland B Walter, MD</last_name>
    </contact>
    <contact_backup>
      <phone>(206) 667-3599</phone>
      <email>rwalter@fredhutch.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>December 10, 2016</study_first_submitted>
  <study_first_submitted_qc>December 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 2, 2017</study_first_posted>
  <last_update_submitted>October 2, 2019</last_update_submitted>
  <last_update_submitted_qc>October 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>Relapsed/Refractory Acute Myeloid Leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

